Abstract：
BACKGROUND: With the prevalence of diabetes reaching an epidemic level, there is a growing interest in the investigation of its remission. Proglucagon-derived peptides (PGDP) have been shown to have a glucose-regulating effect. However, whether they play a role in diabetes remission remains poorly understood.
OBJECTIVE: To investigate changes in plasma levels of PGDP in glycaemic responders versus non-responders.
METHODS: The study was a randomised placebo-controlled trial comprising 18 adults with prediabetes (registered at www.
RESULTS: gov as NCT03889210). Following an overnight fast, participants consumed ketone β-hydroxybutyrate (KEβHB)-supplemented beverage and placebo beverage in crossover manner. Serial blood samples were collected from baseline to 150 min at 30-min intervals. The endpoints were changes in glucagon-like peptide-1 (GLP-1), glicentin, oxyntomodulin, glucagon, and major proglucagon fragment (MPGF). Participants were stratified into the \'responders\' and \'non-responders\' subgroups based on their glycaemic changes following the ingestion of KEβHB. The area under the curve (AUC) was calculated to estimate the accumulated changes in the studied PGDP and compared using paired-t test between the KEβHB and placebo beverages.
RESULTS: Responders had a significantly greater reduction in plasma glucose compared with non-responders following acute ketosis (p < 0.001). The AUC0-150 for oxyntomodulin was significantly lower following the KEβHB beverage compared with the placebo (p = 0.045) in responders, but not in non-responders (p = 0.512). No significant differences in AUCs0-150 were found for GLP-1, glicentin, glucagon, and MPGF in either responders or non-responders.
CONCLUSIONS: Oxyntomodulin is involved in lowering plasma glucose and may play an important role in diabetes remission.
OBJECTIVE: To investigate changes in plasma levels of PGDP in glycaemic responders versus non-responders.
METHODS: The study was a randomised placebo-controlled trial comprising 18 adults with prediabetes (registered at www.
RESULTS: gov as NCT03889210). Following an overnight fast, participants consumed ketone β-hydroxybutyrate (KEβHB)-supplemented beverage and placebo beverage in crossover manner. Serial blood samples were collected from baseline to 150 min at 30-min intervals. The endpoints were changes in glucagon-like peptide-1 (GLP-1), glicentin, oxyntomodulin, glucagon, and major proglucagon fragment (MPGF). Participants were stratified into the \'responders\' and \'non-responders\' subgroups based on their glycaemic changes following the ingestion of KEβHB. The area under the curve (AUC) was calculated to estimate the accumulated changes in the studied PGDP and compared using paired-t test between the KEβHB and placebo beverages.
RESULTS: Responders had a significantly greater reduction in plasma glucose compared with non-responders following acute ketosis (p < 0.001). The AUC0-150 for oxyntomodulin was significantly lower following the KEβHB beverage compared with the placebo (p = 0.045) in responders, but not in non-responders (p = 0.512). No significant differences in AUCs0-150 were found for GLP-1, glicentin, glucagon, and MPGF in either responders or non-responders.
CONCLUSIONS: Oxyntomodulin is involved in lowering plasma glucose and may play an important role in diabetes remission.
摘要：
背景：随着糖尿病的患病率达到流行水平，对其缓解的调查越来越感兴趣。胰高血糖素原衍生肽(PGDP)已显示具有葡萄糖调节作用。然而,它们是否在糖尿病缓解中起作用仍然知之甚少。
目的：研究血糖应答者与非应答者血浆PGDP水平的变化。
方法：该研究是一项随机安慰剂对照试验，包括18名患有糖尿病前期的成年人（在www注册。
结果：govasNCT03889210)。经过一夜的禁食，参与者以交叉方式饮用补充酮β-羟基丁酸酯(KEβHB)的饮料和安慰剂饮料.以30分钟的间隔从基线至150分钟收集系列血液样品。终点是胰高血糖素样肽-1（GLP-1）的变化，Glicentin,胃泌素调节素,胰高血糖素,和主要胰高血糖素原片段(MPGF)。根据摄入KEβHB后的血糖变化，将参与者分为“响应者”和“非响应者”亚组。计算曲线下面积(AUC)以估计所研究的PGDP的累积变化,并使用配对t检验在KEβHB和安慰剂饮料之间进行比较。
结果：急性酮症后，与无反应者相比，反应者的血浆葡萄糖下降幅度明显更大（p<0.001）。与安慰剂（p=0.045）相比，KEβHB饮料后的胃泌酸调节素的AUC0-150显着降低，但非响应者(p=0.512)。GLP-1、Glicentin、胰高血糖素,和MPGF在应答者或非应答者中。
结论：泌酸调节素参与降低血糖，可能在糖尿病缓解中起重要作用。
目的：研究血糖应答者与非应答者血浆PGDP水平的变化。
方法：该研究是一项随机安慰剂对照试验，包括18名患有糖尿病前期的成年人（在www注册。
结果：govasNCT03889210)。经过一夜的禁食，参与者以交叉方式饮用补充酮β-羟基丁酸酯(KEβHB)的饮料和安慰剂饮料.以30分钟的间隔从基线至150分钟收集系列血液样品。终点是胰高血糖素样肽-1（GLP-1）的变化，Glicentin,胃泌素调节素,胰高血糖素,和主要胰高血糖素原片段(MPGF)。根据摄入KEβHB后的血糖变化，将参与者分为“响应者”和“非响应者”亚组。计算曲线下面积(AUC)以估计所研究的PGDP的累积变化,并使用配对t检验在KEβHB和安慰剂饮料之间进行比较。
结果：急性酮症后，与无反应者相比，反应者的血浆葡萄糖下降幅度明显更大（p<0.001）。与安慰剂（p=0.045）相比，KEβHB饮料后的胃泌酸调节素的AUC0-150显着降低，但非响应者(p=0.512)。GLP-1、Glicentin、胰高血糖素,和MPGF在应答者或非应答者中。
结论：泌酸调节素参与降低血糖，可能在糖尿病缓解中起重要作用。
